Novel immune cells linked to dangerous eye blood vessel growth
A new target for blinding eye diseases
Northwestern Medicine researchers have identified a previously unknown group of immune cells that appear to drive pathological blood vessel formation in several blinding eye conditions. The findings, published in the Journal of Clinical Investigation, point to a new therapeutic target for diseases such as wet age-related macular degeneration and diabetic retinopathy. This discovery could reshape how clinicians treat these conditions.
The research team used advanced imaging and single-cell analysis to isolate and characterize this new immune cell population. They found that these cells release inflammatory signals that trigger abnormal blood vessel growth in the retina. This process leads to leakage, scarring, and vision loss. The study provides a clearer map of the cellular machinery behind these diseases.
Why does this matter for patients?
The identified immune cells act as a switch that turns on the vascular response. Blocking their activity could slow or stop the harmful vessel growth. This suggests that therapies aimed at these specific cells might prevent vision loss more effectively than current treatments.
Patients with wet macular degeneration or diabetic eye disease often face repeated injections of anti-VEGF drugs. The new findings indicate that targeting the immune cells directly could reduce the frequency of these treatments. This could improve quality of life and lower long-term costs.
What are the specific eye diseases affected? The study focuses on wet age-related macular degeneration and diabetic retinopathy. Both involve abnormal blood vessel growth in the retina that damages central vision.
Frequently Asked Questions
How were these immune cells identified? Researchers used single-cell sequencing and multiplexed imaging to detect the novel cell population. These techniques allowed them to distinguish these cells from known immune types.
When might new therapies be available? The study is at the discovery stage. Clinical trials targeting these cells are not yet in progress, but the findings open the door for future drug development.